Companies:
49,811
Total Market Cap:
139350487250113.91
Global Rank
#8649
Country Rank
#72
Market Cap
1.2 B
Price
78.03
Change (%)
4.55%
Volume
51,800
Cosmo Pharmaceuticals N.V.'s latest marketcap:
1.2 B
As of 07/05/2025, Cosmo Pharmaceuticals N.V.'s market capitalization has reached $1.2 B. According to our data, Cosmo Pharmaceuticals N.V. is the 8649th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.2 B |
| Revenue (ttm) | 314.99 M |
| Net Income (ttm) | 157.31 M |
| Shares Out | 16.02 M |
| EPS (ttm) | 9.58 |
| Forward PE | 19.97 |
| Ex-Dividend Date | 06/04/2025 |
| Earnings Date | 07/23/2025 |
Market Cap Chart
Data Updated: 07/05/2025
Cosmo Pharmaceuticals N.V.'s yearly market capitalization.
Cosmo Pharmaceuticals N.V. has seen its market value drop from ₣2.09 B to ₣1.2 B since 2014, representing a total decrease of 42.88% and an annual compound decline rate (CAGR) of 5.19%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | ₣1.2 B | -7.09% | 8649 |
| 12/30/2024 | ₣1.02 B | 24.91% | 8184 |
| 12/29/2023 | ₣818.27 M | -18.39% | 8811 |
| 12/30/2022 | ₣1 B | -9.22% | 7882 |
| 12/30/2021 | ₣1.1 B | -10.15% | 8349 |
| 12/30/2020 | ₣1.23 B | 9.61% | 6593 |
| 12/30/2019 | ₣1.12 B | -14.94% | 6269 |
| 12/28/2018 | ₣1.32 B | -40.1% | 5147 |
| 12/29/2017 | ₣2.2 B | -7.8% | 4222 |
| 12/30/2016 | ₣2.39 B | 4.38% | 3528 |
Company Profile
About Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a global pharmaceutical company specializing in the development and commercialization of innovative products for gastroenterology, dermatology, and healthtech solutions.
Key Products & Offerings
- GI Genius: An AI-powered system for real-time detection of colorectal lesions.
- Winlevi: A prescription treatment for acne vulgaris.
- Lialda/Mezavant/Mesavancol: A once-daily mesalamine tablet for ulcerative colitis remission.
- Uceris/Cortiment: An oral budesonide tablet targeting colon inflammation.
- Eleview: An injectable solution for safer gastrointestinal lesion removal.
- Lumeblue: A diagnostic drug for visualizing colorectal lesions.
- Aemcolo/Relafalk: A tablet-based treatment for travelers’ diarrhea.
- Byfavo: An intravenous sedative/anesthetic.
Pipeline & Development
- Breezula: Phase III androgen receptor inhibitor for scalp conditions.
- Rifamycin 1% enema: Phase II trial for distal ulcerative colitis and proctitis.
- Colesevelam: Preclinical studies for bile acid diarrhea.
- Cortexolone 17α-valerate-21-propionate: Phase I trial for solid tumors.
- AI Technology: GI Genius intelligent endoscopy system.
Strategic Partnerships
Cosmo collaborates with leading healthcare companies, including:
- Bausch Health
- Ferring
- China Medical System Holdings Limited
- Medtronic
- RedHill Biopharma Ltd.
- Sun Pharmaceutical Industries Ltd.
- 3SBio
- InfectoPharm
- Hyphens Pharma International Limited
Company Background
Founded in 1997, Cosmo Pharmaceuticals N.V. is headquartered in Dublin, Ireland.
Frequently Asked Questions
-
What is Cosmo Pharmaceuticals N.V.'s (SWX-COPN) current market cap?As of 07/05/2025, Cosmo Pharmaceuticals N.V. (including the parent company, if applicable) has an estimated market capitalization of $1.2 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Cosmo Pharmaceuticals N.V. (SWX-COPN) rank globally by market cap?Cosmo Pharmaceuticals N.V. global market capitalization ranking is approximately 8649 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.